Testing Chemical Safety: What Is Needed to Ensure the Widespread Application of Non-animal Approaches?

Scientists face growing pressure to move away from using traditional animal toxicity tests to determine whether manufactured chemicals are safe. Numerous ethical, scientific, business, and legislative incentives will help to drive this shift. However, a number of hurdles must be overcome in the coming years before non-animal methods are adopted into widespread practice, particularly from regulatory, scientific, and global perspectives. Several initiatives are nevertheless underway that promise to increase the confidence in newer alternative methods, which will support the move towards a future in which less data from animal tests is required in the assessment of chemical safety.

[1]  Fiona Sewell,et al.  Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials. , 2014, Regulatory toxicology and pharmacology : RTP.

[2]  Thomas Hartung,et al.  Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals - a report by the transatlantic think tank for toxicology (t(4)). , 2009, ALTEX.

[3]  Gareth J Waldron,et al.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling , 2012, Nature Reviews Drug Discovery.

[4]  Erwin van Vliet,et al.  Current standing and future prospects for the technologies proposed to transform toxicity testing in the 21st century. , 2011, ALTEX.

[5]  Thomas Singer,et al.  The application of 3D cell models to support drug safety assessment: opportunities & challenges. , 2014, Advanced drug delivery reviews.

[6]  Laura N. Vandenberg,et al.  Non-monotonic dose responses in EDSP Tier 1 guideline assays , 2014 .

[7]  Richard W. Lewis,et al.  A 1-year toxicity study in dogs is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides , 2010, Critical reviews in toxicology.

[8]  Stephen T Holgate,et al.  Animal models of asthma: value, limitations and opportunities for alternative approaches. , 2011, Drug discovery today.

[9]  Erwin van Vliet,et al.  Current standing and future prospects for the technologies proposed to transform toxicity testing in the 21st century. , 2011 .

[10]  Neil Spooner,et al.  Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies. , 2014, Drug discovery today.

[11]  Ian Indans,et al.  Acute toxicity testing of chemicals—Opportunities to avoid redundant testing and use alternative approaches , 2010, Critical reviews in toxicology.

[12]  W. Russell,et al.  Ethical and Scientific Considerations Regarding Animal Testing and Research , 2011, PloS one.

[13]  Thomas Hartung,et al.  Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. , 2013, ALTEX.

[14]  Neil Spooner,et al.  Reducing pre-clinical blood volumes for toxicokinetics: toxicologists, pathologists and bioanalysts unite. , 2014, Bioanalysis.

[15]  D. Paustenbach,et al.  Benzene and human health: A historical review and appraisal of associations with various diseases , 2010, Critical reviews in toxicology.

[16]  Patrice Sutton,et al.  An evidence-based medicine methodology to bridge the gap between clinical and environmental health sciences. , 2011, Health affairs.

[17]  Fiona Sewell,et al.  A global initiative to refine acute inhalation studies through the use of ‘evident toxicity’ as an endpoint: Towards adoption of the fixed concentration procedure , 2014 .